Assay identifies actionable mutations in lymphoid malignancies

Print Friendly, PDF & Email


Researcher in the lab
Photo by Daniel Sone
Researchers say hybrid capture sequencing is an accurate and sensitive method for identifying actionable gene mutations in lymphoid malignancies. This method revealed potentially actionable mutations in 91% of patients studied, who had diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or chronic lymphocytic leukemia... [Read Article]
Print Friendly, PDF & Email

Combo is preferentially active in T-cell lymphomas

Print Friendly, PDF & Email


Lorenzo Falchi, MD
Photo by Larry Young
A 2-drug combination has demonstrated preferential activity in T-cell lymphomas over B-cell lymphomas, according to researchers. In a small, phase 1/2 study, treatment with oral 5-azacitidine and romidepsin produced a higher overall response rate (ORR) and prolonged progression-free survival (PFS) in patients with T-cell lymphomas. “In... [Read Article]
Print Friendly, PDF & Email

Duvelisib combos show promise for PTCL, CTCL

Print Friendly, PDF & Email


Poster reception
at the 10th Annual
T-cell Lymphoma Forum
Photo by Larry Young
Phase 1 results suggest duvelisib combination therapies can be active and well-tolerated in patients with relapsed/refractory T-cell lymphomas. Researchers said duvelisib had an acceptable safety profile when given in combination with romidepsin or bortezomib to patients with relapsed/refractory peripheral T-cell... [Read Article]
Print Friendly, PDF & Email

FDA investigating VTEs related to ECP

Print Friendly, PDF & Email


Red and white blood cells
The US Food and Drug Administration (FDA) says it is evaluating reports of venous thromboembolism (VTE) in patients treated with the CELLEX Photopheresis System by Therakos, Inc. This extracorporeal photopheresis (ECP) device system is FDA-approved for use in patients with cutaneous T-cell lymphoma (CTCL). The system is used... [Read Article]
Print Friendly, PDF & Email